NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma's "Events" page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharm ...

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the "Notes"): $500 million of 5.150% Notes due 2029 (the "2029 Notes"); $500 million of 5.400% Notes due 2034 (the "2034 Notes"); and $500 million of 5.900% Notes due 2054 (the "2054 Notes"). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd. The offering is expec ...

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the "Notes"): $500 million of 5.150% Notes due 2029 (the "2029 Notes"); $500 million of 5.400% Notes due 2034 (the "2034 Notes"); and $500 million of 5.900% Notes due 2054 (the "2054 Notes"). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd. The offering is expec ...

文章核心观点 - 沃拉西尼布是一种针对IDH突变型胶质瘤的靶向治疗药物,如获批将是该类疾病的首个靶向治疗药物 [1][2] - 沃拉西尼布在关键性III期临床试验中展现出前所未有的疗效和耐受性,已获FDA优先审评,预计2024年8月20日获批 [2] - 预计沃拉西尼布在美国市场的年峰值销售将超过10亿美元,有望为Royalty Pharma带来超过1.5亿美元的年度版税收入 [4] 公司相关 - Royalty Pharma以9.05亿美元的现金收购了Agios公司在沃拉西尼布美国销售的部分版税权益 [3] - Royalty Pharma是一家专注于收购生物制药行业专利权和版税的公司,目前已拥有35个商业产品的版税权益 [7][8] - Royalty Pharma表示将继续与创新者合作,为生物制药行业的创新提供资金支持 [7] 行业相况 - 胶质瘤治疗方面近20年来创新乏力,沃拉西尼布作为首个针对IDH突变型胶质瘤的靶向治疗药物具有潜在的变革性 [2] - 美国每年约有1,500例新发IDH突变型弥漫性胶质瘤病例,总体患病人数约为10,000例 [2]

Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumor Pivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy and tolerability; vorasidenib granted priority review with PDUFA date of August 20, 2024 Royalty Pharma projects greater than $1 billion in peak sales annually for vorasidenib in the U.S.; potential to generate royalties exceeding $150 million annually Royalty Pharma to host investor call today, Tuesday, ...

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14 at 9:00 a.m. ETBofA Securities 2024 Healthcare Conference on Wednesday, May 15 at 6:00 p.m. ET / 3:00 p.m. PT The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. Webcasts will also ...

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14 at 9:00 a.m. ET BofA Securities 2024 Healthcare Conference on Wednesday, May 15 at 6:00 p.m. ET / 3:00 p.m. PT The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. Webcasts will also ...

财务数据和关键指标变化 - 公司在第一季度实现了14%的Royalty Receipts增长,这反映了公司多元化投资组合的强劲表现 [9] - 由于2023年第一季度存在非经常性的Biohaven相关付款,Milestones and other contractual receipts下降,导致Portfolio Receipts(公司总收入)下降37% [39] 各条业务线数据和关键指标变化 - 公司的多元化投资组合中,以疾病领域为主的产品如囊性纤维化和Trelegy表现强劲,带动了Royalty Receipts的增长 [38] 各个市场数据和关键指标变化 - 公司没有提及具体市场数据和关键指标变化 公司战略和发展方向及行业竞争 - 公司宣布以约5.25亿美元收购Sanofi的frexalimab的特许权使用费,这是一项具有多适应症潜力的处于开发阶段的疗法 [10][17] - 公司目前拥有15个处于开发阶段的疗法,预计可产生超过10亿美元的峰值特许权使用费 [11][26] - 公司表示将以中单位百分比的年度增幅增加股息 [10] 管理层对经营环境和未来前景的评论 - 公司对自身多元化投资组合的强劲表现以及开发阶段产品的前景表示乐观 [8][51][52][53][54] 问答环节重要的提问和回答 问题1 **Chris Shibutani提问** 询问公司如何评估frexalimab在其他适应症(如Sjogren's、1型糖尿病和狼疮)的潜力 [59] **Marshall Urist回答** 公司的核心论点是基于frexalimab在多发性硬化症上的强劲III期数据,其他适应症的数据还需进一步观察,但可能带来额外的上行空间 [60][61] 问题2 **Geoff Meacham提问** 询问frexalimab是否旨在填补Tysabri在多发性硬化症市场的空缺,以及公司未来是否会更多地部署资本到开发阶段产品 [63] **Pablo Legorreta和Terrance Coyne回答** 公司收购frexalimab是基于其自身的优势,而非针对Tysabri的替代。公司未来会继续保持在已上市和开发阶段产品之间的平衡部署资本 [65][66][67][68][69] 问题3 **Michael DiFiore提问** 询问公司对frexalimab交易中的特许权使用费分成机制以及2025年Medicare Part D改革的影响 [83] **Marshall Urist和Terrance Coyne回答** 公司在frexalimab交易中保留了大部分的特许权使用费,只有在销售额超过20亿美元时才有少量分成。公司认为Medicare Part D改革对其投资组合影响有限 [84][85][90]

For the quarter ended March 2024, Royalty Pharma (RPRX) reported revenue of $717 million, down 36.6% over the same period last year. EPS came in at $0.98, compared to $1.60 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $671.45 million, representing a surprise of +6.79%. The company delivered an EPS surprise of +2.08%, with the consensus EPS estimate being $0.96.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

Royalty Pharma (RPRX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.08%. A quarter ago, it was expected that this company would post earnings of $1.03 per share when it actually produced earnings of $1.15, delivering a surprise of 11.65%.Over the last four quarters, the company ha ...